Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AXSM

Axsome Therapeutics Inc

Sep 12 • 04:00PM ET

118.42

-4.54 -3.69 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ACAD VRTX ALKS NBIX BHVN SAGE PRTA AVDL RARE

| Held by: VTI IWM VB VBK VXF IWO IBB SCHA VTWO IHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.07	Insider Own	17.52%	Shs Outstand	49.82M	Perf Week	-5.39%
Market Cap	5.91B	Forward P/E	106.72	EPS next Y	1.11	Insider Trans	-2.56%	Shs Float	41.16M	Perf Month	8.25%
Enterprise Value	5.83B	PEG	-	EPS next Q	-0.83	Inst Own	75.86%	Short Float	8.53%	Perf Quarter	11.45%
Income	-246.90M	P/S	11.94	EPS this Y	42.10%	Inst Trans	-0.37%	Short Ratio	5.61	Perf Half Y	-2.66%
Sales	495.03M	P/B	80.73	EPS next Y	132.00%	ROA	-41.57%	Short Interest	3.51M	Perf YTD	39.96%
Book/sh	1.47	P/C	19.50	EPS next 5Y	-	ROE	-280.68%	52W High	139.13 -14.89%	Perf Year	27.76%
Cash/sh	6.07	P/FCF	-	EPS past 3/5Y	-20.03% -24.44%	ROIC	-113.24%	52W Low	75.56 56.72%	Perf 3Y	92.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.78%	Volatility	3.86% 2.98%	Perf 5Y	73.28%
Dividend TTM	-	EV/Sales	11.78	EPS Y/Y TTM	22.16%	Oper. Margin	-42.05%	ATR (14)	3.80	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.51	Sales Y/Y TTM	69.83%	Profit Margin	-49.88%	RSI (14)	50.89	Recom	1.05
Dividend Gr. 3/5Y	- -	Current Ratio	1.57	EPS Q/Q	41.82%	SMA20	-1.40%	Beta	0.52	Target Price	175.56
Payout	-	Debt/Eq	3.06	Sales Q/Q	72.13%	SMA50	5.85%	Rel Volume	1.12	Prev Close	122.96
Employees	683	LT Debt/Eq	1.98	Earnings	Aug 04 BMO	SMA200	9.43%	Avg Volume	625.09K	Price	118.42
IPO	Nov 19, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.07% 8.71%	Trades		Volume	700,686	Change	-3.69%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Resumed	Wells Fargo	Overweight	$163
Jul-03-25	Resumed	Morgan Stanley	Overweight	$190
Jun-03-25	Initiated	Oppenheimer	Outperform	$185
Apr-07-25	Initiated	Jefferies	Buy	$200
Feb-11-25	Initiated	Deutsche Bank	Buy	$176
Dec-31-24	Reiterated	Mizuho	Outperform	$124 → $122
Sep-03-24	Initiated	Wells Fargo	Overweight	$140
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy	$95 → $106
Jul-22-24	Initiated	Needham	Buy	$130
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$90 → $115
Mar-19-24	Initiated	Robert W. Baird	Outperform	$108
Feb-06-24	Initiated	UBS	Buy	$111
Jan-25-24	Initiated	RBC Capital Mkts	Outperform	$126
Dec-13-23	Initiated	Citigroup	Buy	$125
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral	$59 → $81
Jan-05-23	Initiated	Piper Sandler	Neutral	$75
Nov-01-22	Initiated	Loop Capital	Buy	$95
Sep-07-22	Resumed	Mizuho	Buy	$49 → $76
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$105 → $34
Jun-10-21	Initiated	Berenberg	Buy	$112

Show Previous Ratings

Sep-09-25 01:07PM	Axsome Therapeutics Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
Sep-04-25 09:00AM	Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years (Motley Fool)
Sep-03-25 11:30AM	Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report? (Zacks)
Sep-02-25 01:05AM	H.C. Wainwright Reaffirms Buy on Axsome (AXSM) Following Generic Challenge to Portfolio (Insider Monkey)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
07:00AM	Loading…
Aug-27-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 06:55PM	ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment (Exec Edge)
Aug-05-25 11:36AM	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
03:09AM	Axsome Therapeutics Inc (AXSM) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Aug-04-25 09:30AM	Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings (Zacks)
08:10AM	Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:12AM	Axsome: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-25 02:00PM	Palantir, Advanced Micro, Walt Disney, Pfizer, ZoomInfo, and More Stocks to Watch This Week (Barrons.com)
Jul-30-25 07:30AM	2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% (Barchart)
10:00AM	Loading…
Jul-29-25 10:00AM	Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-28-25 10:00AM	Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-25 05:51AM	2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now (Motley Fool)
Jul-22-25 09:39AM	ALKS Down Despite Positive Top-Line Data From Narcolepsy Study (Zacks) -6.50%
Jul-21-25 07:30AM	Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline (GlobeNewswire)
07:00AM	Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today (GlobeNewswire)
Jul-09-25 07:00AM	Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 (GlobeNewswire)
Jul-07-25 07:00AM	Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 (GlobeNewswire)
Jul-06-25 04:15AM	Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating (Insider Monkey)
Jul-04-25 07:48AM	Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment (Zacks)
03:23AM	Piper Sandler Reaffirms Price Target on Axsome (AXSM) Despite AXS-14 FDA Hurdle (Insider Monkey)
Jun-20-25 07:00AM	Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month (GlobeNewswire)
Jun-18-25 07:00AM	Axsome Therapeutics to Present Data Spanning the SYMBRAVO (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) (GlobeNewswire)
Jun-16-25 07:00AM	Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders (GlobeNewswire)
Jun-11-25 07:57PM	Axsome's AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley (Insider Monkey)
07:00AM	Loading…
07:00AM	Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 (GlobeNewswire)
Jun-10-25 07:00AM	Axsome Therapeutics Announces Availability of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults (GlobeNewswire)
Jun-09-25 07:00AM	Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia (GlobeNewswire)
Jun-05-25 03:19AM	2 Soaring Stocks Wth More Upside Potential (Motley Fool)
Jun-04-25 11:30AM	Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report? (Zacks)
May-29-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-28-25 07:00AM	Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting (GlobeNewswire)
May-27-25 07:00AM	Axsome Therapeutics Settles SUNOSI (solriamfetol) Patent Litigation with Hetero Labs Ltd. (GlobeNewswire)
May-24-25 06:40AM	3 High-Flying Stocks That Could Soar Even More (Motley Fool)
May-14-25 07:30PM	Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis (Motley Fool)
May-13-25 07:00AM	Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone (GlobeNewswire)
May-12-25 07:08AM	Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years (Motley Fool)
May-11-25 11:15AM	3 Monster Stocks in the Making (Motley Fool)
May-06-25 09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
03:02AM	Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
12:24AM	Q1 2025 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 11:44AM	Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-01-25 07:00AM	Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month (GlobeNewswire)
Apr-30-25 10:01AM	TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
Apr-28-25 10:00AM	Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline (Zacks)
Apr-22-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-10-25 09:52AM	Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? (Zacks) -5.92%
06:18AM	Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy (TipRanks)
Apr-08-25 07:00AM	Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 (GlobeNewswire)
Apr-04-25 07:00AM	Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) -8.37%
Apr-02-25 03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks)
11:29AM	AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol (Zacks)
09:33AM	Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 (Zacks)
Apr-01-25 04:04PM	Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week (Investor's Business Daily)
01:23PM	Why Shares of Axsome Therapeutics Slumped Today (Motley Fool)
07:00AM	Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) (GlobeNewswire)
Mar-26-25 11:51AM	AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint (Zacks)
Mar-25-25 06:47PM	Why Pharma and Biotech Stocks Got Thrashed on Tuesday (Motley Fool) -6.82%
12:53PM	IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. (Investor's Business Daily)
07:00AM	Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint (GlobeNewswire)
Mar-21-25 11:36AM	Axsome: The Alzheimer's Agitation Program For AXS-05 (SeekingAlpha)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
11:30AM	Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-19-25 12:14PM	HRMY Down 10.8% in Six Months: How Should You Play the Stock? (Zacks)
Mar-14-25 10:32AM	Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025? (Insider Monkey)
Mar-05-25 07:00AM	Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA (GlobeNewswire)
Mar-03-25 07:00AM	Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer's Disease Agitation Supporting NDA Submission (GlobeNewswire)
Mar-01-25 05:04PM	Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-26-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-25 01:34PM	Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs (Benzinga) -5.10%
07:00AM	Axsome Therapeutics Announces SYMBRAVO (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors (GlobeNewswire)
Feb-23-25 03:09PM	Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily) +6.70% -5.10%
Feb-19-25 02:48PM	Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025 (Insider Monkey)
02:03AM	Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ... (GuruFocus.com)
01:06AM	Q4 2024 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-18-25 11:15AM	Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00AM	Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-16-25 09:45AM	This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? (Motley Fool)
Feb-11-25 02:42PM	Why Axsome Therapeutics (AXSM) Is Advancing Today (Insider Monkey)
11:39AM	Why Axsome Therapeutics Stock Is Soaring Today (Motley Fool)
03:33AM	Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains? (Zacks)
Feb-10-25 02:45PM	Why Axsome Therapeutics Stock Is Skyrocketing Today (Motley Fool) +20.16%
12:33PM	Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' (Benzinga)
07:00AM	Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY (dextromethorphan HBr bupropion HCl) Patent Litigation (GlobeNewswire)
Jan-31-25 07:00AM	Axsome Therapeutics Hosts SYMBRAVO FDA Approval Virtual Investor Event with Expert Thought Leader (GlobeNewswire)
Jan-30-25 03:45PM	Axsome Therapeutics Announces FDA Approval of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults (GlobeNewswire)
Jan-22-25 07:00AM	Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 (GlobeNewswire) +6.33%
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily) +11.52% -5.23%
07:00AM	Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue (GlobeNewswire)
Dec-31-24 08:15AM	Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results (Benzinga)
Dec-30-24 05:07PM	Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation (Investor's Business Daily)

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Herriot Tabuteau	Officer	Sep 12 '25	Proposed Sale	118.42	27,907	3,304,747		Sep 12 07:19 PM
Coleman Mark	Director	Sep 08 '25	Buy	127.28	1,575	200,466	48,212	Sep 09 08:11 PM
Saad Mark E	Director	Sep 05 '25	Option Exercise	9.00	9,127	82,143	19,129	Sep 05 07:43 PM
Saad Mark E	Director	Sep 05 '25	Sale	125.07	9,127	1,141,514	10,002	Sep 05 07:43 PM
Saad Mark E	Director	Sep 05 '25	Proposed Sale	125.07	9,127	1,141,529		Sep 05 05:08 PM
JEFFS ROGER	Director	Sep 02 '25	Sale	123.68	13,464	1,665,228	57,510	Sep 02 07:11 PM
JEFFS ROGER	Director	Sep 02 '25	Proposed Sale	123.68	13,464	1,665,162		Sep 02 04:01 PM
JEFFS ROGER	Director	Aug 27 '25	Sale	122.30	20,000	2,446,000	110,974	Aug 29 07:08 PM
JEFFS ROGER	Director	Aug 28 '25	Sale	121.60	20,000	2,432,000	90,974	Aug 29 07:08 PM
JEFFS ROGER	Director	Aug 29 '25	Sale	121.27	20,000	2,425,400	70,974	Aug 29 07:08 PM
JEFFS ROGER	Director	Aug 29 '25	Proposed Sale	121.27	20,000	2,425,335		Aug 29 04:02 PM
JEFFS ROGER	Director	Aug 28 '25	Proposed Sale	121.60	20,000	2,432,004		Aug 28 04:04 PM
JEFFS ROGER	Director	Aug 27 '25	Proposed Sale	122.30	20,000	2,446,052		Aug 27 04:12 PM
JEFFS ROGER	Director	Aug 26 '25	Sale	120.03	20,000	2,400,600	130,974	Aug 26 07:00 PM
JEFFS ROGER	Director	Aug 22 '25	Sale	120.08	16,694	2,004,616	150,974	Aug 26 07:00 PM
JEFFS ROGER	Director	Aug 26 '25	Proposed Sale	120.03	20,000	2,400,658		Aug 26 04:08 PM
JEFFS ROGER	Director	Aug 22 '25	Proposed Sale	120.08	16,694	2,004,598		Aug 22 04:28 PM
Murdock Hunter R.	General Counsel	Jun 20 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 23 '25	Option Exercise	29.91	6,014	179,879	6,014	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 20 '25	Sale	102.47	7,500	768,525	0	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 23 '25	Sale	100.12	6,014	602,122	0	Jun 23 07:42 PM
Murdock Hunter R.	Officer	Jun 23 '25	Proposed Sale	100.12	6,014	602,101		Jun 23 04:01 PM
Murdock Hunter R.	Officer	Jun 20 '25	Proposed Sale	102.47	7,500	768,503		Jun 20 04:08 PM
Murdock Hunter R.	General Counsel	Jun 16 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 18 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 17 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 16 '25	Sale	102.42	7,500	768,150	0	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 18 '25	Sale	100.90	7,500	756,750	0	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 17 '25	Sale	100.26	7,500	751,950	0	Jun 18 09:16 PM
Murdock Hunter R.	Officer	Jun 18 '25	Proposed Sale	100.90	7,500	756,729		Jun 18 04:42 PM
Murdock Hunter R.	Officer	Jun 17 '25	Proposed Sale	100.26	7,500	751,975		Jun 17 04:01 PM
Murdock Hunter R.	Officer	Jun 16 '25	Proposed Sale	102.42	7,500	768,154		Jun 16 04:17 PM
Jacobson Mark L.	Chief Operating Officer	Jun 09 '25	Option Exercise	8.02	25,000	200,500	30,783	Jun 10 07:00 PM
Jacobson Mark L.	Chief Operating Officer	Jun 09 '25	Sale	110.44	25,000	2,761,000	5,783	Jun 10 07:00 PM
Jacobson Mark L.	Officer	Jun 09 '25	Proposed Sale	110.44	25,000	2,760,894		Jun 09 04:07 PM
Coleman Mark	Director	May 27 '25	Sale	105.47	3,750	395,512	50,387	May 29 07:00 PM
Coleman Mark	Director	May 28 '25	Sale	103.43	3,750	387,862	46,637	May 29 07:00 PM
Jacobson Mark L.	Chief Operating Officer	May 27 '25	Option Exercise	6.47	20,673	133,754	26,456	May 28 09:52 PM
Jacobson Mark L.	Chief Operating Officer	May 28 '25	Option Exercise	6.47	20,000	129,400	25,783	May 28 09:52 PM
Jacobson Mark L.	Chief Operating Officer	May 27 '25	Sale	104.66	20,673	2,163,636	5,783	May 28 09:52 PM
Jacobson Mark L.	Chief Operating Officer	May 28 '25	Sale	103.45	20,000	2,069,000	5,783	May 28 09:52 PM
Coleman Mark	Director	May 28 '25	Proposed Sale	103.43	3,750	387,858		May 28 05:04 PM
Jacobson Mark L.	Officer	May 28 '25	Proposed Sale	103.45	20,000	2,068,932		May 28 05:03 PM
Jacobson Mark L.	Officer	May 27 '25	Proposed Sale	0.00	20,673	1		May 27 04:46 PM
Coleman Mark	Director	May 27 '25	Proposed Sale	105.47	3,750	395,501		May 27 04:45 PM
Coleman Mark	Director	May 20 '25	Sale	107.49	3,000	322,473	54,137	May 20 09:46 PM
Coleman Mark	Director	May 20 '25	Proposed Sale	107.49	3,000	322,473		May 20 05:54 PM
Pizzie Nick	Chief Financial Officer	Feb 13 '25	Option Exercise	3.50	12,000	42,000	54,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 14 '25	Option Exercise	3.50	3,000	10,500	45,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 13 '25	Sale	129.86	12,000	1,558,320	42,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 14 '25	Sale	131.07	3,000	393,210	42,187	Feb 14 09:20 PM
Pizzie Nick	Officer	Feb 14 '25	Proposed Sale	131.07	3,000	393,202		Feb 14 04:09 PM
Pizzie Nick	Officer	Feb 13 '25	Proposed Sale	129.86	12,000	1,558,312		Feb 13 04:02 PM
Coleman Mark	Director	Jan 03 '25	Option Exercise	9.00	9,127	82,143	57,137	Jan 06 04:06 PM
Coleman Mark	Director	Nov 19 '24	Option Exercise	5.94	33,410	198,455	48,010	Nov 20 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AXSM

Axsome Therapeutics Inc

Upgrade your FINVIZ experience